A phase II study involving the use of sunitinib in the treatment of advanced/metastatic paraganglioma and pheochromocytoma found one patient with MEN2A and a germline RET variant experienced a 64% tumor volume reduction (O'Kane et al., 2019). This evidence concerns the gene RET and hereditary pheochromocytoma-paraganglioma.